NCT04220047 Effects of Left Atrial Appendage Resection and Marshall Ligament Amputation on Clinical Outcome in Patients Undergoing Off-pump Coronary Artery Bypass
| NCT ID | NCT04220047 |
| Status | Recruiting |
| Phase | — |
| Sponsor | China National Center for Cardiovascular Diseases |
| Condition | Coronary Artery Disease |
| Study Type | INTERVENTIONAL |
| Enrollment | 400 participants |
| Start Date | 2020-04-30 |
| Primary Completion | 2021-12-31 |
Eligibility & Interventions
Eligibility Fast-Check
Enter your details for a quick preliminary check. This does not replace medical advice.
What to Expect as a Participant
You will actively receive the study intervention — which may be a drug, biologic, device, or procedure.
This trial targets 400 participants in total. It began in 2020-04-30 with a primary completion date of 2021-12-31.
⚠ This information is for research awareness only. Always consult your physician before joining any clinical trial. Participation is voluntary and you may withdraw at any time.
Brief Summary
Surgical occlusion of the left atrial appendage (LAAO) is sometimes performed during the cardiac surgery to reduce long-term risk of stroke.A previous study found that LAAO may be associated with increased risk of postoperative atrial fibrillation.New-onset atrial fibrillation (NOAF) after coronary artery bypass graft is related to an increased short-term and long term risk of stroke and mortality.Marshall ligament amputation may reduce the occurence of atrial fibrillation. However, little is known whether this approach is justified during the coronary artery bypass graft.Therefore, this study aimed to investigate whether LAAO and Marshall ligament amputation during off-pump coronary artery bypass was associated with reduced risks of postoperative new-onset atrial fibrillation and stroke.
Eligibility Criteria
Inclusion Criteria: * isolated first off-pump coronary artery bypass Exclusion Criteria: * Preoperative atrial fibrillation or a history of atrial fibrillation; * Concurrent cardiac or non-cardiac surgery * Intraoperative convert to bypass bypass surgery * Emergency surgery * History of previous cardiac surgery * Severe organ dysfunction
Contact & Investigator
Hansong Sun, doctor
PRINCIPAL INVESTIGATOR
Chinese Academy of Medical Sciences, Fuwai Hospital
Frequently Asked Questions
Who can join the NCT04220047 clinical trial?
This trial is open to participants of all sexes, aged 18 Years or older, up to 80 Years, studying Coronary Artery Disease. Full inclusion and exclusion criteria are listed in the Eligibility Criteria section. Always confirm your eligibility with the research team before applying.
Is NCT04220047 currently recruiting?
Yes, NCT04220047 is actively recruiting participants. Contact the research team at whcwuhengchao@163.com for enrollment information.
Where is the NCT04220047 trial being conducted?
This trial is being conducted at Beijing, China.
Who is sponsoring the NCT04220047 clinical trial?
NCT04220047 is sponsored by China National Center for Cardiovascular Diseases. The principal investigator is Hansong Sun, doctor at Chinese Academy of Medical Sciences, Fuwai Hospital. The trial plans to enroll 400 participants.